Maeda T, Kusumi E, Kami M, et al. Disseminated tuberculosis following reduced-intensity cord blood transplantation for adult patients with hematological diseases. Bone Marrow Transplant 35: 91

Department of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan.
Bone Marrow Transplantation (Impact Factor: 3.57). 02/2005; 35(1):91-7. DOI: 10.1038/sj.bmt.1704740
Source: PubMed


Allogeneic hematopoietic stem cell transplantation (allo-SCT) recipients are prone to infections. The incidences of mycobacterial infections after allo-SCT in several case series vary from less than 0.1-5.5%. However, no study has been published on tuberculosis following unrelated cord blood transplantation (UCBT). We retrospectively reviewed medical records of 113 adult patients with a median age of 54 years who underwent reduced-intensity UCBT (RI-UCBT) at Toranomon Hospital from March 2002 to May 2004. Mycobacterium tuberculosis infections were diagnosed in three patients (2.7%), of these two patients developed primary infection and one patient developed reactivation of latent tuberculosis. The interval between RI-UCBT and the diagnosis of tuberculosis was 34, 41 and 61 days. All the patients had disseminated disease at diagnosis. Histological examination showed the lack of granuloma in caseous necrosis. Combination antituberculous treatments showed limited efficacy, and two patients died immediately after diagnosis. M. tuberculosis caused life-threatening illness, rapidly progressing in RI-UCBT recipients. The lack of granuloma in caseous necrosis suggests the impaired T-cell function in early post transplant phase of RI-UCBT. We should consider M. tuberculosis in the differential diagnoses of fever of unknown source after RI-UCBT.

Download full-text


Available from: Shigeo Hara, Aug 07, 2014
  • Source
    • "For example, in recipients of T-cell depleted allografts in the United States of America (USA), active TB has been reported in 0.69% of patients and all the reported cases originally came from areas that are endemic for TB (14). At least 25% of M. tuberculosis infections in recipients of HSCT result from reactivation of LTBIs (1, 15, 16). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mycobacterium tuberculosis (M. tuberculosis) infections are uncommon in recipients of hematopoietic stem cell transplantation. These infections are 10 to 40 times commoner in recipients of stem cell transplantation than in the general population but they are 10 times less in stem cell transplantation recipients compared to solid organ transplant recipients. The incidence of M. tuberculosis infections in recipients of allogeneic stem cell transplantation ranges between ˂ 1% and 15% and varies considerably according to the type of transplant and the geographical location. Approximately 80% of M. tuberculosis infections in stem cell transplant recipients have been reported in patients receiving allografts. Several risk factors predispose to M. tuberculosis infections in recipients of hematopoietic stem cell transplantation and these are related to the underlying medical condition and its treatment, the pre-transplant conditioning therapies in addition to the transplant procedure and its own complications. These infections can develop as early as day 11 and as late as day 3337 post-transplant. The course may become rapidly progressive and the patient may develop life-threatening complications. The diagnosis of M. tuberculosis infections in stem cell transplant recipients is usually made on clinical grounds, cultures obtained from clinical specimens, tissues biopsies in addition to serology and molecular tests. Unfortunately, a definitive diagnosis of M. tuberculosis infections in these patients may occasionally be difficult to be established. However, M. tuberculosis infections in transplant recipients usually respond well to treatment with anti-tuberculosis agents, provided the diagnosis is made early. A high index of suspicion should be maintained in recipients of stem cell transplantation living in endemic areas and presenting with compatible clinical and radiological manifestations. High mortality rates are associated with infections caused by multidrug resist
    Frontiers in Oncology 08/2014; 4:231. DOI:10.3389/fonc.2014.00231
  • Source
    • "In recent years, umbilical cord blood has been increasingly utilized as a source of hematopoietic stem cells for transplantation of patients without favorable donors despite its immature immune activity which often leads to a prolonged immunological deficiency and many kinds of early severe infectious complications such as bacteremia, cytomegalovirus disease, tuberculosis and fungal infection (Saavedra et al., 2002, Maeda et al., 2005). The cumulative incidence of adenovirus-induced hemorrhagic cystitis after cord blood transplantation was, however, found to be relatively low (2.8%) among Japanese adults (Tomonari et al., 2006). "

    Hemodialysis - Different Aspects, 11/2011; , ISBN: 978-953-307-315-6
  • Source
    • "TB is a serious and a life threatening infectious complication which may cause fatal sepsis and a rapidly progressive illness in recipients of HSCT [6,7]. TB is relatively rare (incidence 0.6–2.7%) in HSCT patients despite their severely immunocompromised state [6,7,10-13,21-23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculous infections in patients with hematological disorders and hematopoietic stem cell transplant vary in incidence, complications and response to treatment. A retrospective study of patients with various benign and malignant hematological disorders and recipients of hematopoietic stem cell transplant who were treated at Riyadh Armed Forces Hospital, Saudi Arabia between January 1991 and December 2002 and who developed tuberculous infections was conducted. Tuberculous infections occurred in eighteen patients with hematological disorders and hematopoietic stem cell transplant. The main associated factors were: reduced immunity due to the primary hematological disorder, age more than 50 years and the administration of cytotoxic chemotherapy, steroids or radiotherapy. These infections frequently involved the lungs and predominantly occurred in males and in patients with chronic myeloproliferative disorders, myelodysplastic syndrome and acute myeloid leukemia. In patients treated with intravenous cytotoxic chemotherapy, tuberculous infections tended to occur earlier and also tended to be more disseminated compared to infections occurring in patients treated with oral chemotherapy. Anti-tuberculous treatment was given to 16 patients and it was successful in 15 of these patients. Tuberculous infections cause significant morbidity and mortality in patients with various hematological disorders and in recipients of hematopoietic stem cell transplant. The early administration of anti-tuberculous therapy and compliance with drug treatment are associated with successful outcomes while delayed management, drug resistance and the presence of miliary infections are associated with poor prognosis and high mortality rates.
    Annals of Clinical Microbiology and Antimicrobials 02/2007; 6(1):16. DOI:10.1186/1476-0711-6-16 · 2.19 Impact Factor
Show more